Product image of Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone) supplied by GNH India

Meriofert

Active Ingredient:
Follicle-Stimulating Hormone, Luteinising Hormone
Origin:
EU

Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

Follicle-Stimulating Hormone (FSH) and Luteinising Hormone (LH), the active ingredient in Meriofert, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It is employed to stimulate follicular development and ovulation in women with infertility.
GNH India supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ibsa Slovakia S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meriofert is a gonadotropin used in reproductive medicine to address disorders of ovulation and to support assisted reproductive technologies.

  • Infertility due to anovulation: promotes follicular growth and estradiol production to enable ovulation.
  • Controlled ovarian stimulation for assisted reproductive technologies: provides coordinated FSH and LH activity to develop multiple mature follicles.
  • Induction of ovulation in women undergoing IVF: supports the final maturation of oocytes for retrieval.

How It Works

  • Meriofert contains recombinant FSH and LH that bind to their respective receptors on ovarian granulosa and theca cells. Activation of FSH receptors stimulates follicular recruitment, growth, and estradiol synthesis, while LH receptor activation promotes theca cell androgen production and final follicular maturation, culminating in ovulation.

Side Effects

Adverse reactions may occur with any gonadotropin therapy.

Common Side Effects

  • Injection site pain or erythema: mild discomfort at the administration site.
  • Ovarian hyperstimulation syndrome (mild): abdominal bloating and mild discomfort.
  • Headache: transient tension‑type headache.
  • Nausea: mild, self‑limiting gastrointestinal upset.

Serious or Rare Side Effects

  • Ovarian hyperstimulation syndrome (severe): rapid weight gain, ascites, or respiratory distress.
  • Thromboembolic events: rare clot formation requiring urgent medical attention.
  • Allergic reaction: rash, urticaria, or anaphylaxis.
  • Ectopic pregnancy: rare occurrence following assisted reproduction.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient suitability and monitor response.

  • Baseline ovarian assessment: perform ultrasound to estimate follicle count.
  • Monitor estradiol levels: adjust dosing based on serum concentrations.
  • Watch for signs of OHSS: educate patients on symptoms requiring prompt care.
  • Contraindications: avoid in known hypersensitivity to gonadotropins or active ingredients.
  • Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Meriofert may interact with other medications that influence ovarian response or coagulation.

Major Interactions (Avoid)

  • Anticoagulants (e.g., warfarin): increased risk of bleeding with severe OHSS.
  • GnRH antagonists used concurrently without proper protocol: may blunt intended ovarian stimulation.

Moderate Interactions (Monitor Closely)

  • Oral contraceptives: may require a washout period before initiating therapy.
  • Thyroid hormone replacement: altered metabolism may affect ovarian response.
  • Corticosteroids: may mask early signs of OHSS.
  • Dopamine agonists: can affect prolactin levels influencing follicular dynamics.

Frequently Asked Questions

Meriofert is a prescription injectable that combines follicle‑stimulating hormone (FSH) and luteinising hormone (LH) to treat infertility caused by anovulation, to stimulate multiple follicle development for assisted reproductive technologies, and to induce ovulation in women undergoing in‑vitro fertilisation cycles.

The FSH component binds to FSH receptors on ovarian granulosa cells, promoting follicular growth and estradiol production. The LH component activates LH receptors on theca cells, supporting androgen synthesis and final follicular maturation, together leading to ovulation when the treatment course is completed.

The dose of Meriofert is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian reserve, response to monitoring, and the specific assisted reproduction protocol being used.

Meriofert is intended for use before pregnancy to achieve ovulation. It is not administered during an established pregnancy, and safety in breastfeeding has not been established. Women should discuss family planning and lactation considerations with their healthcare provider.

Enquiries are submitted via the product page at gnhindia.com where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Meriofert provides a combined FSH and LH formulation, whereas some alternatives offer FSH alone or separate LH preparations. The combined product can simplify dosing schedules and may better mimic natural ovarian physiology, but the choice depends on individual patient response and clinician preference.

Meriofert must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before use, allow the vial to reach room temperature for a few minutes, inspect for particulate matter, and use aseptic technique for intramuscular or subcutaneous injection.

Meriofert is given by a qualified healthcare professional via intramuscular or subcutaneous injection, typically in the abdomen or thigh. The injection site is rotated to reduce local irritation, and dosing is adjusted according to serial ultrasound and hormone monitoring.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid fluid accumulation, thromboembolic events, and rare allergic reactions such as anaphylaxis. Prompt recognition and medical management are essential if these symptoms develop.

Meriofert is contraindicated in individuals with known hypersensitivity to any of its components, in women with ovarian cysts that could rupture, in patients with uncontrolled thyroid disease, and in those with active malignancy or severe cardiovascular disease where ovarian stimulation is unsafe.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Follicle-Stimulating Hormone, Luteinising Hormone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT